Big players have been carving out a niche in the small but thriving field of poly(ADP-ribose) polymerase (PARP) inhibitors, as long-awaited data roll out that validate the experimental approach.

New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...

Other PARP inhibitors have validated the mechanism of action in cancers of the ovary, breast, prostate and pancreas. IDX-1197 has several key advantages over those commercially available PARP ...

Many PARP inhibitors have been approved to treat BRCA-mutated cancer ... We found that this is not the major mechanism for our nanoparticles. After intravenous injection, our nanoparticles were coated ...

while being much more effective at “trapping” PARP1 to inhibit the DNA damage repair mechanism. “There was a real reason to think that dialling out PARP2 might make PARP inhibitors better ...

AbbVie’s hopes of getting a so-called PARP inhibitor cancer drug to market are fading after its veliparib failed in two late-stage studies. AstraZeneca’s Lynparza (olaparib) is becoming well ...

"This highlights a distinct mechanism of cytotoxicity ... Whalen et al, Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability ...

“With our recently implemented trial protocol, we expect to initiate patient enrollment soon and further investigate stenoparib’s dual mechanisms of action—both as a PARP inhibitor and as a ...

The withdrawal was due to updated information on the negative impact on overall survival seen in two studies with PARP inhibitors in that same setting. The mechanism of action for EIS-12656 is ...

Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...